Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Asset disposition
CC transcript
Quarterly results
Appointed director

GUIDED THERAPEUTICS INC (GTHP) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/17/2017 8-K/A Quarterly results
03/24/2017 8-K/A Form 8-K/A - Current report [Amend]
09/09/2016 8-K/A Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Royalty Agreement, between the Company and Imhoff and Maloof"
12/03/2014 8-K/A Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Form of Warrant",
"Form of Placement Agent Warrant",
"Form of Stock Purchase Agreement",
"Placement Agent Agreement, by and between the Company and Olympus Securities, LLC",
"Guided Therapeutics Announces Pricing of $3.8 Million Public Offering"
06/21/2013 8-K/A Form 8-K/A - Current report [Amend]
05/23/2013 8-K/A Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...
Docs: "Certificate of Designations, Preferences and Rights of Series B Convertible Preferred Stock",
"Securities Purchase Agreement, by and among Guided Therapeutics, Inc. and the Purchasers named therein",
"Form of Warrant (Tranche A)",
"Form of Warrant (Tranche B)",
"Registration Rights Agreement, by and among Guided Therapeutics, Inc. and the Purchasers named therein",
"Guided Therapeutics Announces Private Placement of Convertible Preferred Stock and Warrants NORCROSS, GA – Guided Therapeutics, Inc. today announced that it has entered into definitive agreements with certain accredited investors for the private placement of its convertible preferred stock and warrants to purchase shares of its common stock. Gross proceeds to Guided Therapeutics are expected to be approximately $2.6 million, prior to the payment of placement agent fees and expenses. Pursuant to the terms of the definitive agreements, Guided Therapeutics has agreed to issue an aggregate of up to approximately 2,600 shares of preferred stock, which are convertible by the holders at any time into an aggregate of up to approximately 3,823,529 shares of common stock at an initial conversion pr..."
11/28/2011 8-K/A Form 8-K/A - Current report [Amend]
04/30/2010 8-K/A Form 8-K/A - Current report [Amend]
11/06/2007 8-K/A Form 8-K/A - Current report [Amend]
06/05/2007 8-K/A Form 8-K/A - Current report [Amend]
05/15/2007 8-K/A Form 8-K/A - Current report [Amend]
03/14/2007 8-K/A Form 8-K/A - Current report [Amend]
05/19/2003 8-K/A Form 8-K/A - Current report [Amend]
05/19/2003 8-K/A Form 8-K/A - Current report [Amend]
03/14/2002 8-K/A Form 8-K/A - Current report [Amend]

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy